The Combination of Bortezomib, Doxorubicin, and Dexamethasone (PAD) Is an Effective Regimen for High Risk, Newly Diagnosed, Patients with Multiple Myeloma, Reduces Bone Resorption and Normalizes Angiopoietin-1 to Angiopoietin-2 Ratio.

Authors
Publication date
1 January 2007
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Pergamos : Unified Institutional Repository / Digital Library Platform of the National and Kapodistrian University of Athens

    redirect
    oaioai:lib.uoa.gr:uoadl:2951319
    Last time updated on 10/02/2023